Literature DB >> 23232271

Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER Study.

Davide L Vetrano1, Matteo Tosato, Giuseppe Colloca, Eva Topinkova, Daniela Fialova, Jacob Gindin, Henriëtte G van der Roest, Francesco Landi, Rosa Liperoti, Roberto Bernabei, Graziano Onder.   

Abstract

OBJECTIVE: Pharmacological treatment of older adults with cognitive impairment represents a challenge for prescribing physicians, and polypharmacy is common in these complex patients. The aim of the current study is to assess prevalence and factors related to polypharmacy in a sample of nursing home (nursing home) residents with advanced cognitive impairment.
METHODS: We conducted a cross-sectional analysis of 1449 nursing home residents with advanced cognitive impairment participating to the Services and Health for Elderly in Long Term Care (SHELTER) project, a study collecting information on residents admitted to 57 nursing home in eight countries. Data were collected using the International Resident Assessment Instrument (InterRAI) for long-term care facilities. Polypharmacy status was categorized into three groups: nonpolypharmacy (zero to four drugs), polypharmacy (five to nine drugs), and excessive polypharmacy (≥10 drugs).
RESULTS: Polypharmacy was observed in 735 residents (50.7%) and excessive polypharmacy was seen in 245 (16.9%). Compared with nonpolypharmacy, excessive polypharmacy was associated directly with ischemic heart disease (odds ratio [OR], 3.68; 95% confidence interval [CI], 2.01-6.74), diabetes mellitus (OR, 2.66; 95% CI; 1.46-4.84), Parkinson's disease (OR, 2.84; 95% CI, 1.36-5.85), gastrointestinal symptoms (OR, 1.20; 95% CI, 1.43-3.39), pain (OR, 3.12; 95% CI, 1.99-4.89), dyspnea (OR, 2.57; 95% CI, 1.31-5.07), and recent hospitalization (OR, 2.56; 95% CI, 1.36-5.85). An inverse relation with excessive polypharmacy was shown for age (OR, 0.74; 95% CI, 0.59-0.93), activities of daily living disability (OR, 0.79; 95% CI, 0.63-0.99) and presence of a geriatrician on the nursing home staff (OR, 0.36; 95% CI, 0.20-0.64).
CONCLUSION: Polypharmacy and excessive polypharmacy are common among nursing home residents with advanced cognitive impairment. Determinants of polypharmacy status includes not only comorbidities, but also specific symptoms, age, and functional status. A geriatrician in the facility is associated with lower prevalence of excessive polypharmacy.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nursing home; Older adults; Polypharmacy

Mesh:

Year:  2012        PMID: 23232271     DOI: 10.1016/j.jalz.2012.09.009

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  14 in total

Review 1.  Recommendations to prescribe in complex older adults: results of the CRIteria to assess appropriate Medication use among Elderly complex patients (CRIME) project.

Authors:  Graziano Onder; Francesco Landi; Domenico Fusco; Andrea Corsonello; Matteo Tosato; Miriam Battaglia; Simona Mastropaolo; Silvana Settanni; Manuela Antocicco; Fabrizia Lattanzio
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

2.  A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.

Authors:  Brenna N Renn; Ali Abbas Asghar-Ali; Stephen Thielke; Angela Catic; Sharyl R Martini; Brian G Mitchell; Mark E Kunik
Journal:  Am J Geriatr Psychiatry       Date:  2017-10-10       Impact factor: 4.105

3.  Laxative use among older adults with intellectual disability: a cross-sectional observational study.

Authors:  Hadiah AlMutairi; Máire O'Dwyer; Elish Burke; Mary McCarron; Philip McCallion; Martin C Henman
Journal:  Int J Clin Pharm       Date:  2019-12-02

4.  Polypharmacy, potentially inappropriate medication and cognitive status in Austrian nursing home residents: results from the OSiA study.

Authors:  Reinhard Alzner; Ulrike Bauer; Stefan Pitzer; Maria Magdalena Schreier; Jürgen Osterbrink; Bernhard Iglseder
Journal:  Wien Med Wochenschr       Date:  2016-02-05

5.  Polypharmacy Increases Risk of Dyspnea Among Adults With Serious, Life-Limiting Diseases.

Authors:  Kathleen M Akgün; Supriya Krishnan; Shelli L Feder; Janet Tate; Jean S Kutner; Kristina Crothers
Journal:  Am J Hosp Palliat Care       Date:  2019-09-24       Impact factor: 2.500

6.  Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials.

Authors:  Kristin Kahle-Wrobleski; Howard Fillit; Jonathan Kurlander; Catherine Reed; Mark Belger
Journal:  Eur J Health Econ       Date:  2014-11-20

7.  Development and application of medication appropriateness indicators for persons with advanced dementia: a feasibility study.

Authors:  Carole Parsons; Laura McCann; Peter Passmore; Carmel Hughes
Journal:  Drugs Aging       Date:  2015-01       Impact factor: 3.923

8.  Factors associated with polypharmacy and excessive polypharmacy in older people with intellectual disability differ from the general population: a cross-sectional observational nationwide study.

Authors:  Máire O'Dwyer; Jure Peklar; Philip McCallion; Mary McCarron; Martin C Henman
Journal:  BMJ Open       Date:  2016-04-04       Impact factor: 2.692

9.  The epidemiology of polypharmacy in older adults: register-based prospective cohort study.

Authors:  Lucas Morin; Kristina Johnell; Marie-Laure Laroche; Johan Fastbom; Jonas W Wastesson
Journal:  Clin Epidemiol       Date:  2018-03-12       Impact factor: 4.790

10.  Building interpretable models for polypharmacy prediction in older chronic patients based on drug prescription records.

Authors:  Simon Kocbek; Primoz Kocbek; Andraz Stozer; Tina Zupanic; Tudor Groza; Gregor Stiglic
Journal:  PeerJ       Date:  2018-10-12       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.